Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BTW (Bitway) fluctuates by 56.4% in 24 hours: trading volume surge triggers intense price volatility

BTW (Bitway) fluctuates by 56.4% in 24 hours: trading volume surge triggers intense price volatility

Bitget PulseBitget Pulse2026/04/28 09:14
Show original
By:Bitget Pulse

Brief Description of Volatility

In the past 24 hours, the price of BTW rebounded from a low of $0.016629 to a high of $0.026, currently quoted at $0.022202, with a price swing of 56.4%. Trading volume has significantly expanded to around $16.65 to $16.85 million, more than 50% higher than the previous day, showing clear signs of net capital inflow, with a market capitalization of approximately $48 to $50 million.

Brief Analysis of the Cause of Fluctuation

- Surge in trading volume as the main factor: Bitget data shows that BTW fluctuated by 42.3% within 24 hours, accompanied by a surge in trading volume, driving prices up rapidly from the lows before a correction.

- No clear official announcement or listing event, only routine on-chain activity observed, and no large-scale whale transfer records found.

Market Opinions and Outlook

The community and market sentiment remain short-term active but cautious. There is limited discussion on platform X, with primary focus on the overall crypto market risk appetite warming up. Analysts warn of risks from corrections under high volatility and advise monitoring whether subsequent trading volumes continue to expand to confirm the trend.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23